Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a … Read more
Cullinan Oncology LLC (CGEM) - Total Assets
Latest total assets as of September 2025: $484.13 Million USD
Based on the latest financial reports, Cullinan Oncology LLC (CGEM) holds total assets worth $484.13 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cullinan Oncology LLC - Total Assets Trend (2012–2024)
This chart illustrates how Cullinan Oncology LLC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cullinan Oncology LLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Cullinan Oncology LLC's total assets of $484.13 Million consist of 66.7% current assets and 33.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.4% |
| Accounts Receivable | $3.00 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Cullinan Oncology LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cullinan Oncology LLC's current assets represent 66.7% of total assets in 2024, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, up from 0.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Cullinan Oncology LLC Competitors by Total Assets
Key competitors of Cullinan Oncology LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cullinan Oncology LLC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cullinan Oncology LLC generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cullinan Oncology LLC is currently not profitable relative to its asset base.
Cullinan Oncology LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.45 | 24.46 | 14.82 |
| Quick Ratio | 10.45 | 24.46 | 14.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $309.48 Million | $ 567.84 Million | $ 197.96 Million |
Cullinan Oncology LLC - Advanced Valuation Insights
This section examines the relationship between Cullinan Oncology LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 0.97 |
| Asset Growth Rate (YoY) | 28.4% |
| Total Assets | $621.82 Million |
| Market Capitalization | $605.86 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cullinan Oncology LLC's assets close to their book value ( 0.97x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Cullinan Oncology LLC's assets grew by 28.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cullinan Oncology LLC (2012–2024)
The table below shows the annual total assets of Cullinan Oncology LLC from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $621.82 Million | +28.43% |
| 2023-12-31 | $484.18 Million | -13.71% |
| 2022-12-31 | $561.12 Million | +28.35% |
| 2021-12-31 | $437.19 Million | +103.62% |
| 2020-12-31 | $214.71 Million | +113.72% |
| 2019-12-31 | $100.46 Million | +190.01% |
| 2018-12-31 | $34.64 Million | +1008342.50% |
| 2016-12-31 | $3.44K | +2811.02% |
| 2015-12-31 | $118.00 | -99.28% |
| 2014-12-31 | $16.34K | -28.15% |
| 2013-12-31 | $22.74K | +127.44% |
| 2012-12-31 | $10.00K | -- |